最新发布
水稻+抗性禾本科杂草：首个具有酰胺结构的HPPD分子正在进入”验证期”
编者按：美国环保署（EPA）近日公布，已收到日产化学株式会社提交的两项Iptriazopyrid产品登记申请，分别为98.5%原药（Technical）和100 g/L悬浮剂（SC），拟用途均为水稻田除草。目前，两项申请仍处于EPA审查及公…
6家农药上市公司2026半年报新出炉：利尔、泰禾、丰山、新农、农心、广康
大农化网报道： 近日，利尔化学、泰禾股份、丰山集团、新农股份、农心科技和广康生化等农药上市公司披露2026年半年度报告，业绩表现如下： 利尔化学： 核心产品量价助涨营收、汇兑损失吞噬利润 2026年上半年，公司实现营业收入481,594.6…
泰禾股份2026上半年营收净利双增，创制药环丙氟虫胺销售2.83亿元
大农化网报道：8月28日，南通泰禾化工股份有限公司（简称″泰禾股份″）披露2026年半年度报告。 2026年上半年，公司实现营业收入297,333.93万元，同比增长23.23%；归属于上市公司股东的净利润24,094.16万元，同比增长3…
EU microplastics ban pushes beauty from ingredient swaps to manufacturing change
The European Union (EU) is cracking down on microplastics intentionally added to cosmetics due to their environmental persistence. Turning to bio-based formulations could help cosmetic manufacturers skirt upcoming bottlenecks, but at scale, these materials present formulation challenges. Experts suggest that it may be time for the beauty industry to update its manufacturing processes.
Molecular Pathways Driving Autoantibody Production Following SARS-CoV-2 Infection Identified
When the immune system encounters a virus, it produces antibodies designed to recognize and eliminate the invader. But in some people infected with SARS-CoV-2 the immune response goes awry, producing autoantibodies that mistakenly attack the body’s own tissues.
AgriFood Signals: Reservoir & Deere partnership, 80 Acres Farms lawsuit, new blended finance for Africa
AgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foo…
英国修订噻螨酮与茚虫威最大残留限量，2027年1月正式生效
世界农化网中文网报道：近日，英国健康与安全执行局（HSE）发布公告，对噻螨酮（hexythiazox）和茚虫威（indoxacarb）两种农药活性成分在部分农产品中的最大残留限量（MRLs）进行了修订。新限量已于2026年7月25日正式通过，并将于2027年1月25日起生效执行，以便贸易伙伴和食品经营者有时间适应新的限量标准。
Heidelberg Pharma deepens ADC alliance with Huadong
Why it matters: The companies plan to combine their technologies and development capabilities, including Heidelberg Pharma’s proprietary ATAC technology, which uses amanitin as a payload, with Huadong’s research and development capabilities.
Notch Signaling Switch Enables Scalable Helper T Cell Production for CAR T
A new Stem Cell Reports study describes a scalable method for generating CD4+ helper T cells from induced pluripotent stem cells (iPSCs). The work, which was done by scientists at Boston University’s Center for Regenerative Medicine (CReM) and Boston Medical Center, could boost efforts to generate off-the-shelf CAR T-cell therapies for use in patients with cancers and chronic inflammatory diseases. Their paper is aptly titled “ Generation of effector CD4+ T cells from human iPSC .”
CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial
Immunotherapies, like CAR T-cell therapy, are well known in the cancer field. But they can also be used to treat autoimmune disorders. Now, six patients with severe rheumatoid arthritis (RA) have received this treatment at Charité—Universitätsmedizin Berlin. The results from the world’s first clinical trial showed that disease activity decreased substantially in all participants. By the end of the observation period, three of the patients no longer required any medication for their RA.